BBI Director elected Fellow of the Royal Society

Prof Dek Woolfson, Director of the Bristol BioDesign Institute, has been elected to the Fellowship of the Royal Society, one of over 90 “outstanding researchers from across the world” to have received the honour this year. These include Prof Jonathan Clayden, who also works in the University of Bristol’s School of Chemistry.

Professor Woolfson’s research is at the intersection between chemistry and biology. He applies chemical methods and principles to understand biological phenomena related to proteins. His group focuses on designing completely new protein structures and functions from scratch, and using these living cells to study natural biological functions.

Professor Woolfson said: “I was completely bowled over to learn that I had been elected a Fellow of the Royal Society. This is an honour for me personally, but, more importantly, it is recognition of my co-workers’ research over the past 30 years or so. Much of this work has been done at Bristol. I’m indebted to my fantastic colleagues in Chemistry, Biochemistry, and across the University for their collaboration, collegiality, and friendship over the last 20 years.”

Professor Clayden’s research focuses on designing and building molecules that have controlled but flexible three-dimensional architectures. His work has shown that dynamic molecules of this type can react in unusual and useful ways, or exhibit behaviours characteristic of much more complex biological counterparts.

The new reactions he has discovered allow a range of molecular structures of value in medicinal chemistry to be made with remarkable efficiency. Professor Clayden is also author of a globally acclaimed undergraduate textbook on Organic Chemistry.

Professor Clayden said: “I’m completely delighted, and extremely honoured, to have been elected as a Fellow of the Royal Society, recognising the ways that we have managed to harness the power of molecular synthesis to explore and illuminate broader scientific concepts.

“This honour is a recognition of the creativity and dedication of the outstanding co-workers I have been privileged to work with in my research group, and it underlines what outstanding, stimulating and collaborative places Bristol, and before that Manchester, have been (and still are!) to do imaginative and inventive science.”

As Fellows of the Royal Society, Professors Woolfson and Clayden join the ranks of Stephen Hawking, Isaac Newton, Charles Darwin, Albert Einstein, Lise Meitner, Subrahmanyan Chandrasekhar and Dorothy Hodgkin.

Sir Adrian Smith, President of the Royal Society, said: “It is with great pleasure that I welcome the latest cohort of outstanding researchers into the Fellowship of the Royal Society.

“Their achievements represent the very best of scientific endeavour, from basic discovery to research with real-world impact across health, technology and policy. From tackling global health challenges to reimagining what AI can do for humanity, their work is a testament to the power of curiosity-driven research and innovation.”

(The above news story – with the exception of the first paragraph – was first published by University of Bristol)

BBI runs session at SynBioBeta 2025

The BBI ran a session on turning breakthrough health innovations into real world impact at SynBioBeta 2025, held from 5-8 May in San Jose, California.

The event brought together over 1,500 attendees from more than 50 countries, including scientists, entrepreneurs, investors, and policymakers, to explore the latest advancements in synthetic biology.

Key themes of the conference included AI & Digital Biology, Biomanufacturing Scale-Up, Human Health and Longevity, and Planetary Health.

The BBI team of Dr Kerstin Kinkelin, Dr Kathleen Sedgley, Prof Ash Toye and Prof Darryl Hill from University of Bristol, and Dr Francis Lister from Science Creates, were hosting a Lunch & Learn session to highlight the Bristol innovation ecosystem.

Ash showcased Scarlet Therapeutics (a University of Bristol spinout) and its therapeutic red blood cell technology, and Darryl presented a new, groundbreaking technology for rapid bacterial detection.

The conference was attended by a large delegation from the UK, including representatives from across the innovation ecosystem as well as former science minister and current Chair of the Regulatory Innovation Office, Lord David Willetts.

Thanks to everyone who attended and asked so many questions, and thanks to Fiona Mischel and John Cumbers from SynBioBeta for the opportunity to present.

ADDovenom: Pioneering new snakebite treatment

A five-minute video about the ADDovenom project has been released. The film includes interviews with Profs Christiane Schaffitzel (University of Bristol) and Nick Casewell (LSTM), who highlight the numbers killed and injured by snake bites every year, and the drawbacks of current antivenom treatments. They explain how the goal of ADDovenom is to create a more effective, accessible, and cheaper therapeutic.

UKRI highlights BBI work on COVID-19 in article on structural biology research

The UKRI has published an article celebrating the history of BBSRC-supported impact in structural biology, which mentions the research on the SARS-CoV-2 virus by BBI researchers Profs Christiane Berger-Schaffitzel and Imre Berger.

The article (Advances in structural biology research) says:

Professors Christiane Berger-Schaffitzel and Imre Berger at the University of Bristol were pooling their teams’ expertise to study how membrane proteins fold.

Their work was supported by BBSRC responsive mode and ALERT research equipment funding, the Wellcome Trust, and BrisSynBio, one of six synthetic biology centres in the UK. BrisSynBio was funded by BBSRC and EPSRC, and Professor Imre Berger is the director of the centre.

When the pandemic started, they pivoted to COVID-19 as part of University of Bristol’s UNCOVER, a COVID-19 emergency research group led by Professor Adam Finn from Bristol Medical School (PHS).

Using cryogenic electron microscopy, where researchers freeze samples and fire electrons to image proteins, they determined the 3D structure of SARS-CoV-2’s spike protein. They discovered a pocket in the spike protein that they showed contained linoleic acid, an essential fatty acid with key roles in regulating the immune response.

Collaborating with virologist Professor Andrew Davidson and his team, they found that binding linoleic acid to the spike blocked the virus from infecting and replicating, acting as an antiviral. Two medical doctors in the US began using linoleic acid as an emergency COVID-19 treatment. Work is ongoing to develop this technology and establish full regulatory approval for this therapy in the UK.

To achieve approval and bring the drug to patients, University of Bristol spin-out Halo Therapeutics Ltd was founded by Dr Daniel Fitzgerald (CEO), Professor Christiane Berger-Schaffitzel (Chief Technology Officer) and Professor Imre Berger (Chief Strategy Officer).

Halo is developing structure-based drugs to target unmet needs around disease treatment. The spin-out is leading the application for clinical trials for the fatty acid antiviral drug on patients.

If successful, the drug could be used to treat early infections or for those who have been in contact with an infected individual to prevent infection and transmission.

Halo is also not stopping at COVID-19, turning its attention to other respiratory infections and potential obesity treatments based on fatty acid metabolism, too.

Vaccine Hub team hold annual meeting

The Future Vaccines Manufacturing Research Hub has held its Annual Meeting at Imperial College London, with BBI Co-Director Prof Imre Berger leading the team from University of Bristol. This was a follow up to the launch event in Bristol in November 2023.

Imre says: “These were fantastic days of great science, inspiring talks, and dynamic discussions. Exciting new ideas and projects are emerging from our partnerships with colleagues in the UK and Vietnam, especially with our long-standing collaborators from Vabiotech in Hanoi. Great science, great partnerships – looking forward to working together to bring the best vaccines and production tools to Vietnam!”

Further info about this partnership is available here.

Dr Kathleen Sedgley: engineering biology and the importance of Scientific Managers

Dr Kathleen SedgleyDr Kathleen Sedgley, the BBI’s Scientific Manager, has recorded a short video talking about her career for the UKRI’s Engineering Biology showcase. The showcase highlights some of the outcomes of the UKRI’s £800m of investment in this field since 2007.

You can read more about Kathleen and watch the video here.

PhD Studentships available with SWBio DTP

*Applications are now closed*

The South West Biosciences Doctoral Training Partnership (SWBio DTP) has launched its latest round of PhD projects, which will begin in September 2025.

The closing date for applications is Wednesday 11 December 2024, and you can apply here.

The following fully-funded, four-year PhD studentships are available with BBI researchers at University of Bristol.

Other projects can be found here.

Synthetic and Engineering Biology: A joint opportunity for the UK and Switzerland

Informed by roundtable discussions held at the Synthetic & Engineering Biology British-Swiss Summit, the Synthetic & Engineering Biology: A joint opportunity for the UK and Switzerland report, published in September 2024, delves into the most pressing challenges for advancing synthetic and engineering biology technologies addressing climate and environmental issues, and poses specific recommendations to governments, industry and the entire innovation ecosystem to act upon.

This webinar, which took place on 22 October 2024, saw Kerstin Kinkelin (Bristol BioDesign Institute), Maddie Cass (BIA), and Anike Te (Lucideon) discuss the report and its recommendations.

These findings are intended for a variety of stakeholders with the aim of moving forward joint Swiss and UK challenges in the field of synthetic and engineering biology, and – in light of the climate crisis – emphasising the urgent need to accelerate the commercialisation of these technologies.

The Summit was organised by the Bristol BioDesign Institute (University of Bristol), the Swiss Business Hub UK & Ireland, the BIA, and Lucideon.

Dek Woolfson to receive Vincent du Vigneaud Award

Prof Dek Woolfson, Director of the Bristol BioDesign Institute, has been named as one of the two recipients of the 2025 Vincent du Vigneaud Award. These prestigious awards, given by the American Peptide Society (and sponsored by Bachem), recognize outstanding achievements in peptide research at mid-career.

Dek has been honoured alongside Prof Ashraf Brik (Technion-Israel Institute of Technology). The awards will be presented at the 29th American Peptide Symposium and 15th International Peptide Symposium in California (15-19 June 2025).

Vincent du Vigneaud was an American biochemist known for his work with sulfur compounds and peptides. He won the 1955 Nobel Prize in Chemistry for his work on the cyclic peptide, oxytocin.

BBI attends UKRI Engineering Biology Programme Convening Event

Engineering Biology Mission Award Holders Professors Thomas Gorochowski and Christiane Berger-Schaffitzel, Aegis Professor of Engineering Biology Anike Te, and BBI Scientific Manager Kathleen Sedgley were attended the UKRI Technology Missions Fund (TMF) Engineering Biology Programme Convening Event in Cardiff on Thursday 3 October.

The two Mission Awards were both highlighted amongst the UKRI portfolio:

  • Haemotoxic and cytotoxic snake venom metalloproteinases – production, enzymatic specificity, snakebite treatment, and biomedical use (PI: Christiane Berger-Schaffitzel)
    The team will establish robust production of snake venom metalloproteinase (SVMPs) toxins ready for use to develop next generation toxin-specific therapies for tackling snakebite envenoming.
  • CYBER – Cyanobacteria Engineering for Restoring Environments (PI: Thomas Gorochowski)
    CYBER aims to develop the foundational multidisciplinary tools needed to de-risk environmentally focused engineering biology and ultimately support its future deployment into real-world ecosystems.

Anike Te (Chief Strategy Officer, Lucideon) joined a panel of experts discussing pathways to commercialisation.

During the meeting, UKRI announced the publication of the Synthetic Biology for Growth evaluation report, which features many of the impacts from BrisSynBio and the broader Bristol synthetic and engineering biology community and partnerships.